{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:02:37Z","timestamp":1794333757119,"version":"4.9.0"},"reference-count":362,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105451","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:55:32Z","timestamp":1782431732000},"page":"105451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacological strategies for glioblastoma: Current therapies, challenges, and emerging targets"],"prefix":"10.1016","volume":"226","author":[{"given":"J.","family":"Hoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tomanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105451_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cncr.11041","article-title":"Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study","volume":"97","author":"Agarwala","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib3","first-page":"222","article-title":"Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy","volume":"3","author":"Agnihotri","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.critrevonc.2026.105451_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","article-title":"ATRX, a guardian of chromatin","volume":"39","author":"Aguilera","year":"2023","journal-title":"Trends Genet."},{"key":"10.1016\/j.critrevonc.2026.105451_bib5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor development and angiogenesis in adult brain tumor: glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40364-024-00676-9","article-title":"From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy","volume":"12","author":"Ahmadi","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib7","doi-asserted-by":"crossref","first-page":"TPS3165","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3165","article-title":"A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors","volume":"41","author":"Ahnert","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0028-3843(14)60408-4","article-title":"The role of the PTEN gene in malignant gliomas","volume":"44","author":"Alexiou","year":"2010","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fphar.2021.680021","article-title":"Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments","volume":"12","author":"Alghamri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib10","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/j.wneu.2023.10.102","article-title":"Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study","volume":"181","author":"Alimohamadi","year":"2024","journal-title":"World Neurosurg."},{"key":"10.1016\/j.critrevonc.2026.105451_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155401","article-title":"A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets","volume":"260","author":"Alimohammadi","year":"2024","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105451_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41388-021-02056-1","article-title":"Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma","volume":"41","author":"Alzial","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib14","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049362","article-title":"RAS and beyond: the many faces of the neurofibromatosis type 1 protein","volume":"15","author":"Anastasaki","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.critrevonc.2026.105451_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111536","article-title":"Advances in Glioblastoma Therapy: An Update on Current Approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib16","first-page":"397","article-title":"Adult type diffuse gliomas in the new 2021 WHO Classification","volume":"114","author":"Antonelli","year":"2022","journal-title":"Pathol. - J. Ital. Soc. Anat. Pathol. Diagn. Cytopathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jscr\/rjae517","article-title":"Glioblastoma multiforme in a patient with neurofibromatosis type 1: a case report and review of literature","volume":"2024","author":"Ayasa","year":"2024","journal-title":"J. Surg. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441460","article-title":"Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration","volume":"14","author":"Bae","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s42003-023-04815-0","article-title":"The therapeutic potential of neurofibromin signaling pathways and binding partners","volume":"6","author":"B\u00e1ez-Flores","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib20","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s12672-025-02815-6","article-title":"Unlocking new horizons: advances in treating IDH-mutant, 1p\/19q-codeleted oligodendrogliomas","volume":"16","author":"Bao","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71187","article-title":"Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine","volume":"14","author":"Barati","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091279","article-title":"Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment","volume":"11","author":"Barresi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.1835","article-title":"Dopamine signaling: target in glioblastoma","volume":"5","author":"Bartek","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105451_bib25","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.3390\/cancers13164226","article-title":"Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications","volume":"13","author":"Basheer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/brain\/awz044","article-title":"The landscape of the mesenchymal signature in brain tumours","volume":"142","author":"Behnan","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2026.105451_bib27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fnins.2021.781160","article-title":"From cell states to cell fates: how cell proliferation and neuronal differentiation are coordinated during embryonic development","volume":"15","author":"Belmonte-Mateos","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000208000","article-title":"What are the roles of oligodendrocyte precursor cells in normal and pathologic conditions?","volume":"101","author":"Benarroch","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/neuonc\/now102","article-title":"The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma","volume":"18","author":"Bernard-Arnoux","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117987","article-title":"Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges","volume":"186","author":"Bhutani","year":"2025","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105451_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccell.2018.06.006","article-title":"Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development","volume":"34","author":"Binder","year":"2018","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105451_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.critrevonc.2026.105451_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198581","article-title":"The association between race and survival in glioblastoma patients in the US: A retrospective cohort study","volume":"13","author":"Bohn","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105451_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s11689-024-09565-6","article-title":"Unraveling neuronal and metabolic alterations in neurofibromatosis type 1","volume":"16","author":"Botero","year":"2024","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.critrevonc.2026.105451_bib35","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","article-title":"MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review","volume":"23","author":"Brandner","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007\u20132011","volume":"51","author":"Brodbelt","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib37","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.0022-202X.2004.22501.x","article-title":"p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma","volume":"122","author":"Brown","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT Status as a Clinical Biomarker in Glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6501031","article-title":"Mechanisms of endogenous neuroprotective effects of astrocytes in brain injury","volume":"2018","author":"Bylicky","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.critrevonc.2026.105451_bib40","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-023-40579-1","article-title":"Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib41","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1523\/JNEUROSCI.1589-18.2018","article-title":"Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma","volume":"39","author":"Caragher","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071783","article-title":"Sex-Specific Differences in Glioblastoma","volume":"10","author":"Carrano","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105451_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12192-014-0537-0","article-title":"Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells","volume":"20","author":"Castro","year":"2015","journal-title":"Cell. Stress. Chaperon-.-."},{"key":"10.1016\/j.critrevonc.2026.105451_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-025-04992-4","article-title":"Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience","volume":"173","author":"Cerretti","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.critrevonc.2026.105451_bib45","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma subclassifications and their clinical significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.critrevonc.2026.105451_bib46","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","article-title":"A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib47","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07918","article-title":"Cancer-associated TERT promoter mutations abrogate telomerase silencing","volume":"4","author":"Chiba","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2026.105451_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib50","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib51","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-associated hypermutation in gliomas","volume":"20","author":"Choi","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib52","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib53","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/genes14040790","article-title":"ATRX\/DAXX: guarding the genome against the hazards of ALT","volume":"14","author":"Clatterbuck Soper","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105451_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105451_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111801","article-title":"Impact of age and gender on glioblastoma onset, progression, and management","volume":"211","author":"Colopi","year":"2023","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.critrevonc.2026.105451_bib57","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","article-title":"Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib58","doi-asserted-by":"crossref","first-page":"34935","DOI":"10.18632\/oncotarget.26183","article-title":"Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma","volume":"9","author":"Da Ros","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105451_bib59","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.critrevonc.2026.105451_bib60","article-title":"Advancements in glioma care: focus on emerging neurosurgical techniques","volume":"12","author":"De Simone","year":"2024","journal-title":"Biomed. [Online]"},{"key":"10.1016\/j.critrevonc.2026.105451_bib61","first-page":"44","article-title":"Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis","volume":"2","author":"Demoulin","year":"2012","journal-title":"Am. J. Blood Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29040840","article-title":"Synergistic effects of temozolomide and doxorubicin in the treatment of glioblastoma multiforme: enhancing efficacy through combination therapy","volume":"29","author":"Dhungel","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105451_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.603647","article-title":"The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices","volume":"14","author":"Di Cintio","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib64","article-title":"Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution","volume":"12","author":"Di Nunno","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib65","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.3390\/ijms251810008","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in cancer: current use and future prospects","volume":"25","author":"Dickerson","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib66","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib67","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105451_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pbc.20803","article-title":"MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma","volume":"48","author":"Donson","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib69","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/pharmaceutics14102072","article-title":"Elastin-like Polypeptide Hydrogels for Tunable, Sustained Local Chemotherapy in Malignant Glioma","volume":"14","author":"Dragojevic","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105451_bib70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT\u2014Regulation and Roles in Cancer Formation","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib71","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cancers12102972","article-title":"Therapeutic Potential of PI3K\/AKT\/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress","volume":"12","author":"Duan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib72","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: First Global Approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2026.105451_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/ol.2022.13632","article-title":"Molecular targeted therapy: A new avenue in glioblastoma treatment","volume":"25","author":"El Atat","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105451_bib74","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-10-2393","article-title":"Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors","volume":"17","author":"Endo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13081882","article-title":"Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies","volume":"13","author":"Esparza-Salazar","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib76","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/1471-2164-11-701","article-title":"DNA methylation in glioblastoma: impact on gene expression and clinical outcome","volume":"11","author":"Etcheverry","year":"2010","journal-title":"BMC Genom."},{"key":"10.1016\/j.critrevonc.2026.105451_bib77","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/ijms25042316","article-title":"Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities","volume":"25","author":"Ezzati","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","article-title":"Association of patterns of care, prognostic factors, and use of radiotherapy\u2013temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study","volume":"142","author":"Fabbro-Peray","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.388","article-title":"O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas","volume":"4","author":"Fan","year":"2013","journal-title":"Cell. Death & Dis."},{"key":"10.1016\/j.critrevonc.2026.105451_bib80","first-page":"1141","article-title":"Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas","volume":"21","author":"Fan","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/cancers16020331","article-title":"The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer","volume":"16","author":"Fang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae108","article-title":"Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma","volume":"6","author":"Fares","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib83","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.wneu.2019.11.077","article-title":"Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining","volume":"135","author":"Faried","year":"2020","journal-title":"World Neurosurg."},{"key":"10.1016\/j.critrevonc.2026.105451_bib84","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-025-06448-9","article-title":"Application of EGFR-TKIs in brain tumors, a breakthrough in future?","volume":"23","author":"Feng","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib85","first-page":"157","article-title":"The 2021 World Health Organization classification of gliomas: an imaging approach","volume":"56","author":"Fernandes","year":"2023","journal-title":"Radiol. Bras."},{"key":"10.1016\/j.critrevonc.2026.105451_bib86","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib88","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib89","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuron.2013.10.037","article-title":"Neural Stem Cells: Generating and Regenerating the Brain","volume":"80","author":"Gage","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.critrevonc.2026.105451_bib90","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/1098612X12445146","article-title":"Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment","volume":"14","author":"Gagnon","year":"2012","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.critrevonc.2026.105451_bib91","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","article-title":"Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy","volume":"10","author":"Galstyan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40139-012-0006-3","article-title":"Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression","volume":"1","author":"Galv\u00e3o","year":"2013","journal-title":"Curr. Pathobiol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib93","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib94","first-page":"vdad115","article-title":"Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect","volume":"5","author":"Gibson","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib95","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/1078155220967087","article-title":"Temozolomide-induced aplastic anaemia: Case report and review of the literature","volume":"27","author":"Gilbar","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2026.105451_bib96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib97","doi-asserted-by":"crossref","first-page":"vii6","DOI":"10.1093\/neuonc\/noy090","article-title":"Survivorship in adults with malignant brain and other central nervous system tumor from 2000 to 2014","volume":"20","author":"Gittleman","year":"2018","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib98","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.31304","article-title":"Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor","volume":"124","author":"Goss","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040356","article-title":"Typical Pediatric Brain Tumors Occurring in Adults-Differences in Management and Outcome","volume":"9","author":"Greuter","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib100","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of Glioblastoma Multiforme\u2013Literature Review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib101","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105451_bib102","doi-asserted-by":"crossref","first-page":"14982","DOI":"10.1038\/s41598-022-19175-8","article-title":"Mechanosensitive expression of the mesenchymal subtype marker connective tissue growth factor in glioblastoma","volume":"12","author":"Grundy","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib103","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53285","article-title":"Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial","volume":"6","author":"Guo","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.critrevonc.2026.105451_bib104","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/modpathol.2012.210","article-title":"Expanding the spectrum of IDH1 mutations in gliomas","volume":"26","author":"Gupta","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2347-8659.139717","article-title":"Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment","volume":"1","author":"Ha","year":"2014","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.critrevonc.2026.105451_bib106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccell.2021.01.005","article-title":"H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model","volume":"39","author":"Haag","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105451_bib107","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14728222.2018.1487953","article-title":"Mutant ATRX: uncovering a new therapeutic target for glioma","volume":"22","author":"Haase","year":"2018","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2026.105451_bib108","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026179","article-title":"Somatic TP53 Mutations in the Era of Genome Sequencing","volume":"6","author":"Hainaut","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib109","first-page":"vdab075","article-title":"A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib110","first-page":"3485","article-title":"PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis","volume":"9","author":"Han","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib111","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105451_bib113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib114","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1593\/neo.10688","article-title":"Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance","volume":"12","author":"Hatanpaa","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105451_bib115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jocn.2017.10.087","article-title":"Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma","volume":"47","author":"Hauser","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib116","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2017.00322","article-title":"Alpha Thalassemia\/Mental Retardation Syndrome X-Linked, the Alternative Lengthening of Telomere Phenotype, and Gliomagenesis: Current Understandings and Future Potential","volume":"7","author":"He","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib117","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib119","first-page":"10","article-title":"Bispecific antibodies: advancing precision oncology","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib120","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105451_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.002","article-title":"Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders\u2019 Collaborative Consortium (EORTC 1419)","volume":"189","author":"Hertler","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib122","first-page":"vdac097","article-title":"Prognostic impact of PDGFRA gain\/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma","volume":"4","author":"Higa","year":"2022","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040794","article-title":"EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylome Profiling","volume":"10","author":"H\u00f6lzl","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib124","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/neuonc\/noae211","article-title":"Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres","volume":"27","author":"Hong","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1215\/15228517-2009-025","article-title":"IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas","volume":"11","author":"Ichimura","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib126","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-22-0201","article-title":"A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma","volume":"21","author":"Iurlaro","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib127","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11060-025-05171-1","article-title":"Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation","volume":"175","author":"Iusupovskaia","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1010632309113","article-title":"The INK4A\/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth","volume":"51","author":"Ivanchuk","year":"2001","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib129","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.1007\/s00330-022-08850-z","article-title":"Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication","volume":"32","author":"Jang","year":"2022","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102438","article-title":"The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane","volume":"24","author":"Jang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105451_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.851877","article-title":"Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis","volume":"12","author":"Jang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib132","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.apsb.2023.10.007","article-title":"Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation","volume":"14","author":"Jastrz\u0119bski","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105451_bib133","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14791\/btrt.2014.2.1.36","article-title":"Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature","volume":"2","author":"Jeong","year":"2014","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105451_bib134","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme\u2014A Literature Review and Clinical Outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib135","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/curroncol30020147","article-title":"Temozolomide chronotherapy in glioma: a systematic review","volume":"30","author":"Jia","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib136","doi-asserted-by":"crossref","first-page":"709","DOI":"10.18632\/oncotarget.588","article-title":"Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas","volume":"3","author":"Jiao","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105451_bib137","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.wneu.2021.06.033","article-title":"Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases","volume":"153","author":"Jiao","year":"2021","journal-title":"World Neurosurg."},{"key":"10.1016\/j.critrevonc.2026.105451_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib139","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1655360","article-title":"Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors","volume":"8","author":"Kaffes","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-019-03243-7","article-title":"Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma","volume":"144","author":"Kaley","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib141","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/acn3.51009","article-title":"Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma","volume":"7","author":"Kaley","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib142","series-title":"Glioblastoma Multiforme","author":"Kanderi","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105451_bib143","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","article-title":"Temozolomide for immunomodulation in the treatment of glioblastoma","volume":"20","author":"Karachi","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib144","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.3390\/cancers13194976","article-title":"Predicting Overall Survival Time in Glioblastoma Patients Using Gradient Boosting Machines Algorithm and Recursive Feature Elimination Technique","volume":"13","author":"Karami","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mad.2011.10.009","article-title":"Somatic mutations in aging, cancer and neurodegeneration","volume":"133","author":"Kennedy","year":"2012","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.critrevonc.2026.105451_bib146","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib148","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4143\/crt.2015.473","article-title":"Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105451_bib149","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/biomedicines11030675","article-title":"Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells","volume":"11","author":"Kim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1677\/ERC-07-0285","article-title":"Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas","volume":"15","author":"Kiss","year":"2008","journal-title":"Endocr. -Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib151","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1215\/15228517-2008-090","article-title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts","volume":"11","author":"Kitange","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib152","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10143-025-03437-w","article-title":"A systematic review of high-grade glioma associated with Li-Fraumeni syndrome","volume":"48","author":"Kite","year":"2025","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.critrevonc.2026.105451_bib153","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/0008-5472.CAN-14-3122","article-title":"Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms","volume":"75","author":"Klingler","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib154","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","article-title":"STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression","volume":"11","author":"Kohsaka","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.critrevonc.2026.105451_bib156","article-title":"ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability","volume":"3","author":"Koschmann","year":"2016","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib157","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4161\/cbt.7.9.6954","article-title":"PTEN Signaling pathways in glioblastoma","volume":"7","author":"Koul","year":"2008","journal-title":"Cancer Biol. & Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115174","article-title":"Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy","volume":"165","author":"Krajcer","year":"2023","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105451_bib159","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-025-05049-2","article-title":"Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis","author":"Lally","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib160","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: First Approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2026.105451_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107922","article-title":"Genotoxic therapy and resistance mechanism in gliomas","volume":"228","author":"Lang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib162","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-13-0350","article-title":"The molecular balancing act of p16(INK4a) in cancer and aging","volume":"12","author":"LaPak","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib163","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/neuonc\/noy091","article-title":"Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","article-title":"Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer","volume":"25","author":"Le\u00e3o","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib166","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40478-018-0598-x","article-title":"Oligodendrogliomas, IDH-mutant and 1p\/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts","volume":"6","author":"Lee","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib167","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40478-023-01622-w","article-title":"MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value","volume":"11","author":"Leske","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib168","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1074\/jbc.M112.411603","article-title":"Alpha thalassemia\/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress","volume":"288","author":"Leung","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105451_bib169","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s11658-023-00514-0","article-title":"Role of N6-methyladenosine methylation in glioma: recent insights and future directions","volume":"28","author":"Li","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105451_bib170","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib171","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201796659","article-title":"ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization","volume":"38","author":"Li","year":"2019","journal-title":"Embo J."},{"key":"10.1016\/j.critrevonc.2026.105451_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152888","article-title":"Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy","volume":"230","author":"Li","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib173","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/brainsci14070687","article-title":"Neuroinflammation in Glioblastoma: Progress and Perspectives","volume":"14","author":"Li","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib174","doi-asserted-by":"crossref","first-page":"9951","DOI":"10.1073\/pnas.1016912108","article-title":"c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib175","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.2147\/IJGM.S418837","article-title":"Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma","volume":"16","author":"Liang","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib176","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11523-015-0372-y","article-title":"Histone Deacetylase Inhibitors Resensitize EGFR\/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition","volume":"11","author":"Liffers","year":"2016","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib177","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105451_bib178","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. & Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010114","article-title":"An Update on Neurofibromatosis Type 1-Associated Gliomas","volume":"12","author":"Lobbous","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib180","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/life13040905","article-title":"Neural Stem Cells as Potential Glioblastoma Cells of Origin","volume":"13","author":"Loras","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105451_bib181","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib182","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib183","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2476842","article-title":"PTEN Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K\/AKT\/hTERT Pathway in Lung Adenocarcinoma A549 Cells","volume":"2016","author":"Lu","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105451_bib184","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12885-024-11848-z","article-title":"Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00401-022-02478-5","article-title":"Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1","volume":"144","author":"Lucas","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib186","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/cr.2009.56","article-title":"Adult neural stem cells in the mammalian central nervous system","volume":"19","author":"Ma","year":"2009","journal-title":"Cell. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.662064","article-title":"CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma","volume":"15","author":"Maggs","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib188","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.critrevonc.2026.105451_bib189","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64846","article-title":"NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1","volume":"10","author":"Marques","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.critrevonc.2026.105451_bib190","doi-asserted-by":"crossref","first-page":"19999","DOI":"10.1038\/s41598-021-99278-w","article-title":"BRAF mutations may identify a clinically distinct subset of glioblastoma","volume":"11","author":"McNulty","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib191","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s13311-022-01251-6","article-title":"Updates in IDH-Wildtype Glioblastoma","volume":"19","author":"Melhem","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.critrevonc.2026.105451_bib192","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in Isocitrate Dehydrogenase 1\u2013Mutated Advanced Glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib193","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a Dual Inhibitor of Mutant IDH1\/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib194","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bjc.6604017","article-title":"Temozolomide induces senescence but not apoptosis in human melanoma cells","volume":"97","author":"Mhaidat","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216711","article-title":"Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study","volume":"588","author":"Miele","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105451_bib197","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5685","article-title":"Age-related somatic mutations in the cancer genome","volume":"6","author":"Milholland","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105451_bib198","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fphys.2021.740939","article-title":"Traumatic Brain Injury: Mechanisms of Glial Response","volume":"12","author":"Mira","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib199","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","article-title":"Neurofibromin and suppression of tumorigenesis: beyond the GAP","volume":"41","author":"Mo","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib200","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib201","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1158\/0008-5472.CAN-17-2269","article-title":"Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma","volume":"78","author":"Mukherjee","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189243","article-title":"TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance","volume":"1880","author":"Murugan","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib203","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/brain\/awl165","article-title":"Essential protective roles of reactive astrocytes in traumatic brain injury","volume":"129","author":"Myer","year":"2006","journal-title":"Brain"},{"issue":"_2","key":"10.1016\/j.critrevonc.2026.105451_bib204","article-title":"Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical","volume":"3","author":"Ahmed","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100812","article-title":"The role of IDH1 mutation on gene expression in glioblastoma","volume":"28","author":"Najafi","year":"2022","journal-title":"Inform. Med. Unlocked"},{"key":"10.1016\/j.critrevonc.2026.105451_bib206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1750-3639.2001.tb00388.x","article-title":"p14ARF deletion and methylation in genetic pathways to glioblastomas","volume":"11","author":"Nakamura","year":"2001","journal-title":"Brain Pathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib207","doi-asserted-by":"crossref","first-page":"70","DOI":"10.14791\/btrt.2023.0042","article-title":"Lynch Syndrome-Associated Glioblastoma Treated With Concomitant Chemoradiotherapy and Immune Checkpoint Inhibitors: Case Report and Review of Literature","volume":"12","author":"Nakase","year":"2024","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105451_bib208","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Network","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib209","series-title":"Handbook of Brain Tumor Chemotherapy","article-title":"CHAPTER 35 - Chemotherapy for Brain Metastases","author":"Newton","year":"2006"},{"key":"10.1016\/j.critrevonc.2026.105451_bib210","doi-asserted-by":"crossref","unstructured":"Nguyen, M.K., Jelinek, M., Singh, A., Isett, B., Myers, E.S., Mullett, S.J., Eisele, Y., Beumer, J., Parise, R., Urban, J., Rose, A., Sellitto, L., Singh, K., Doerfler, R., Dadey, R.E., Kim, C., Rhee, J.C., Davar, D., Villaruz, L.C., Burgess, M., Drappatz, J., Mantica, M., Goodman, A.E., Wang, H., Singhi, A.D., Luke, J.J., Zandberg, D.P. & Bao, R. 2025. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. medRxiv.","DOI":"10.1101\/2025.07.19.25331848"},{"key":"10.1016\/j.critrevonc.2026.105451_bib211","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1440-1789.2011.01204.x","article-title":"Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study","volume":"31","author":"Nobusawa","year":"2011","journal-title":"Neuropathology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib212","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2026.105451_bib213","doi-asserted-by":"crossref","DOI":"10.1242\/dev.156059","article-title":"Neural stem cells: origin, heterogeneity and regulation in the adult mammalian brain","volume":"146","author":"Obernier","year":"2019","journal-title":"Development"},{"key":"10.1016\/j.critrevonc.2026.105451_bib214","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cas.15617","article-title":"TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations","volume":"114","author":"Oguchi","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib215","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib216","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051147","article-title":"TERT Promoter Alterations in Glioblastoma: A Systematic Review","volume":"13","author":"Olympios","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib217","first-page":"513","article-title":"Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib218","doi-asserted-by":"crossref","DOI":"10.3174\/ajnr.A7462","article-title":"The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know","author":"Osborn","year":"2022","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib219","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \"state of the science\" review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib220","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib221","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib222","doi-asserted-by":"crossref","first-page":"19","DOI":"10.31083\/ph.2018.7806","article-title":"Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability","volume":"73","author":"Otreba","year":"2018","journal-title":"Pharmazie"},{"key":"10.1016\/j.critrevonc.2026.105451_bib223","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112773","article-title":"Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)","volume":"13","author":"Padovan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114491","article-title":"New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies","volume":"161","author":"Pandey","year":"2023","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105451_bib225","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041249","article-title":"CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement","volume":"15","author":"Pant","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib226","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fonc.2020.01663","article-title":"One-Year Outcome of Multiple Blood\u2013Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma","volume":"10","author":"Park","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib227","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.21873\/anticanres.12930","article-title":"Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration","volume":"38","author":"Pasqualetti","year":"2018","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib228","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/01616412.2019.1638018","article-title":"The effect of race on the prognosis of the glioblastoma patient: a brief review","volume":"41","author":"Patel","year":"2019","journal-title":"Neurol. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib229","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13046-021-02082-7","article-title":"The HIF1\u03b1-PDGFD-PDGFR\u03b1 axis controls glioblastoma growth at normoxia\/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin","volume":"40","author":"Peng","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib230","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1593\/neo.07721","article-title":"Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody","volume":"9","author":"Perera","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105451_bib231","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ijrobp.2010.03.013","article-title":"Glioblastoma in Children: A Single-Institution Experience","volume":"80","author":"Perkins","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105451_bib232","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Human. Genom."},{"key":"10.1016\/j.critrevonc.2026.105451_bib233","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1593\/neo.09230","article-title":"The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases","volume":"11","author":"Pillay","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105451_bib234","first-page":"vdab171","article-title":"Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study","volume":"3","author":"Poon","year":"2021","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib236","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma Stem Cells: Driving Resilience through Chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib237","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10048-024-00793-5","article-title":"Epigenetic dysregulation in glioblastoma: potential pathways to precision medicine","volume":"26","author":"Prakash","year":"2024","journal-title":"Neurogenetics"},{"key":"10.1016\/j.critrevonc.2026.105451_bib238","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","article-title":"GD2 CAR T cells against human glioblastoma","volume":"5","author":"Prapa","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib239","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IJGM.S397550","article-title":"Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients","volume":"16","author":"Priambada","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184473","article-title":"Stage specific requirement of platelet-derived growth factor receptor-alpha in embryonic development","volume":"12","author":"Qian","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105451_bib241","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib242","first-page":"426","article-title":"Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis","volume":"8","author":"Regev","year":"2021","journal-title":"Neurooncol Pract."},{"key":"10.1016\/j.critrevonc.2026.105451_bib243","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib244","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105451_bib245","first-page":"1","article-title":"Neuro-oncology practice: Understanding inherited genetic risk of adult glioma - A review","volume":"3","author":"Rice","year":"2015","journal-title":"Neuro-Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2026.105451_bib246","series-title":"Neurooncology - Newer Developments","article-title":"Genetic Alterations of Glioblastoma","author":"Richterov\u00e1","year":"2016"},{"key":"10.1016\/j.critrevonc.2026.105451_bib247","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","article-title":"Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies","volume":"42","author":"Rizwani","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib248","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/genes15040501","article-title":"Principles in the Management of Glioblastoma","volume":"15","author":"Roda","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105451_bib249","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cei.13668","article-title":"Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches","volume":"206","author":"Roesler","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fonc.2018.00448","article-title":"Epigenetic Targeting of Glioblastoma","volume":"8","author":"Romani","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib251","first-page":"3002","article-title":"Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review","volume":"24","author":"Ron","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105451_bib252","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-08-1547","article-title":"Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD\/activator protein-1 transcriptional activity","volume":"69","author":"Rong","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib253","doi-asserted-by":"crossref","first-page":"vi283","DOI":"10.1093\/neuonc\/noz219.1195","article-title":"Atim-49 (Ltbk-01). Amg 596, a Novel Anti-Egfrviii Bispecific T Cell Engager (Bite(\u00ae)) Molecule for the Treatment of Glioblastoma (Gbm): Planned Interim Analysis in Recurrent Gbm (Rgbm)","volume":"21","author":"Rosenthal","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102187","article-title":"Starting points for the development of new targeted therapies for glioblastoma multiforme","volume":"51","author":"Rusak","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib255","article-title":"O (6)-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment","volume":"19","author":"Sak","year":"2025","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib256","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.3390\/jcm14072518","article-title":"Potential Biomarkers for IDH-Mutant and IDH-Wild-Type Glioblastomas: A Single-Center Retrospective Study","volume":"14","author":"Sarac","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib257","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-021-03877-6","article-title":"Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial","volume":"155","author":"Saran","year":"2021","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.critrevonc.2026.105451_bib258","series-title":"Stroke (Sixth Edition)","article-title":"60 - Enhancing Stroke Recovery with Cellular Therapies","author":"Savitz","year":"2016"},{"key":"10.1016\/j.critrevonc.2026.105451_bib259","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.lpm.2018.03.011","article-title":"Impact on the brain of the inflammatory response to surgery","volume":"47","author":"Saxena","year":"2018","journal-title":"Presse Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib260","first-page":"444","article-title":"Temozolomide-related hematologic toxicity","volume":"36","author":"Scaringi","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.critrevonc.2026.105451_bib261","unstructured":"Scarpace, L., Mikkelsen, T., Cha, S., Rao, S., Tekchandani, S., Gutman, D., Saltz, J.H., Erickson, B.J., Pedano, N., Flanders, A.E., Barnholtz-Sloan, J., Ostrom, Q., Barboriak, D., & Pierce, L.J. 2016. The Cancer Genome Atlas Glioblastoma Multiforme Collection (TCGA-GBM)."},{"key":"10.1016\/j.critrevonc.2026.105451_bib262","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/ijms23010352","article-title":"Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas","volume":"23","author":"Scheer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib263","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.916682","article-title":"Cyclin-dependent kinase inhibitors in malignant hematopoiesis","volume":"12","author":"Schirripa","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib264","first-page":"vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-023-00359-y","article-title":"Integrated molecular and clinical analysis of BRAF-mutant glioma in adults","volume":"7","author":"Schreck","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib266","first-page":"242","article-title":"Pediatric Brain Tumors: An Update","volume":"46","author":"Segal","year":"2016","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"10.1016\/j.critrevonc.2026.105451_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119673","article-title":"MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives","volume":"1871","author":"Shaw","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.critrevonc.2026.105451_bib268","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5668","article-title":"Targeting drug resistance in glioblastoma (Review)","volume":"65","author":"Sherman","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib269","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s13205-025-04493-1","article-title":"Evolving therapeutic strategies in glioblastoma: traditional approaches and novel interventions","volume":"15","author":"Shetty","year":"2025","journal-title":"3 Biotech"},{"key":"10.1016\/j.critrevonc.2026.105451_bib270","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jocn.2020.04.016","article-title":"Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images","volume":"76","author":"Shimizu","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib271","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-025-00597-9","article-title":"Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics","volume":"14","author":"Shou","year":"2025","journal-title":"Exp. Hematol. & Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib272","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1002\/cam4.1666","article-title":"The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival","volume":"7","author":"Shu","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib273","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033844","article-title":"miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis","volume":"7","author":"Silber","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105451_bib274","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug. Resist."},{"key":"10.1016\/j.critrevonc.2026.105451_bib275","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib276","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216316","article-title":"Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues","volume":"24","author":"Slika","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib277","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00401-020-02144-8","article-title":"Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features","volume":"139","author":"Sloan","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib278","doi-asserted-by":"crossref","DOI":"10.1177\/09603271241241796","article-title":"Risk factors for glioblastoma are shared by other brain tumor types","volume":"43","author":"Smith","year":"2024","journal-title":"Human. & Exp. Toxicol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib279","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/jnci\/93.16.1246","article-title":"PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme","volume":"93","author":"Smith","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105451_bib280","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1158\/0008-5472.CAN-08-2084","article-title":"Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a\/p14ARF\/p15INK4b in glioblastoma multiforme","volume":"68","author":"Solomon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib281","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3390\/biomedicines11082254","article-title":"Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome","volume":"11","author":"Soltan","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib282","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib283","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-013-1302-4","article-title":"Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma","volume":"116","author":"Spratt","year":"2014","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.critrevonc.2026.105451_bib284","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1434495","article-title":"EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma","volume":"14","author":"Sterner","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib285","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-20-0508","article-title":"Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII","volume":"20","author":"Sternjak","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib286","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105451_bib287","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib288","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194836","article-title":"H3F3A K27M Mutation Promotes the Infiltrative Growth of High-Grade Glioma in Adults by Activating \u03b2-Catenin\/USP1 Signaling","volume":"14","author":"Sun","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib289","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00401-021-02395-z","article-title":"Oligosarcomas, IDH-mutant are distinct and aggressive","volume":"143","author":"Suwala","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib290","series-title":"Glioblastoma","article-title":"Epidemiology and Outcome of Glioblastoma","author":"Tamimi","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105451_bib291","doi-asserted-by":"crossref","DOI":"10.3390\/cells14070494","article-title":"Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions","volume":"14","author":"Tang","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105451_bib292","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.754365","article-title":"Perifosine, a Bioavailable Alkylphospholipid Akt Inhibitor, Exhibits Antitumor Activity in Murine Models of Cancer Brain Metastasis Through Favorable Tumor Exposure","volume":"11","author":"Taniguchi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib293","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fphar.2024.1394997","article-title":"Targeting the epidermal growth factor receptor (EGFR\/ErbB) for the potential treatment of renal pathologies","volume":"15","author":"Tawengi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib294","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/jcm9010084","article-title":"Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment","volume":"9","author":"Teleanu","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib295","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1038\/s41598-019-43173-y","article-title":"Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations","volume":"9","author":"Teo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib296","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1166207","article-title":"An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?","volume":"13","author":"Teraiya","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib297","first-page":"90","article-title":"The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas","volume":"38","author":"Terzi","year":"2022","journal-title":"Turk. Patoloji Derg."},{"key":"10.1016\/j.critrevonc.2026.105451_bib298","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/ene.12647","article-title":"Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome","volume":"22","author":"Therkildsen","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib299","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101236","article-title":"From OPC to Oligodendrocyte: An Epigenetic Journey","volume":"8","author":"Tiane","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105451_bib300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib301","series-title":"Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies","article-title":"Chapter 22 - Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma","author":"Tomiyama","year":"2021"},{"key":"10.1016\/j.critrevonc.2026.105451_bib302","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1286683","article-title":"Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations","volume":"11","author":"Tornesello","year":"2023","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib303","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.humpath.2018.04.014","article-title":"Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1\/2) mutations","volume":"78","author":"Toth","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib304","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1111\/cas.16297","article-title":"MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma","volume":"115","author":"Uchihara","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib305","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1590\/S1807-59322011001000013","article-title":"Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma","volume":"66","author":"Uno","year":"2011","journal-title":"Clinics"},{"key":"10.1016\/j.critrevonc.2026.105451_bib306","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12094-012-0916-x","article-title":"Impact of radiotherapy delay on survival in glioblastoma","volume":"15","author":"Valduvieco","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib307","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","article-title":"Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells","volume":"38","author":"Vengoji","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib308","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cac2.12361","article-title":"An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment","volume":"42","author":"Verdugo","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib309","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105451_bib310","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41392-023-01628-9","article-title":"Astrocytes in human central nervous system diseases: a frontier for new therapies","volume":"8","author":"Verkhratsky","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib311","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105451_bib312","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.humpath.2015.05.014","article-title":"Clinicopathologic implications of NF1 gene alterations in diffuse gliomas","volume":"46","author":"Vizca\u00edno","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib313","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105451_bib314","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/neuonc\/noy195","article-title":"Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013","volume":"21","author":"Walker","year":"2019","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib315","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105451_bib316","article-title":"Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib317","first-page":"5833","article-title":"The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers","volume":"11","author":"Wang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib318","first-page":"4183","article-title":"Somatic mutations of PTEN in glioblastoma multiforme","volume":"57","author":"Wang","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib319","article-title":"Impacts of NF1 Gene Mutations and Genetic Modifiers in Neurofibromatosis Type 1","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib320","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1172\/JCI65634","article-title":"Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span","volume":"123","author":"Watson","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105451_bib321","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105451_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116806","article-title":"Reprogramming of astrocytes and glioma cells into neurons for central nervous system repair and glioblastoma therapy","volume":"176","author":"Wei","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105451_bib323","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11060-015-1920-0","article-title":"The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis","volume":"125","author":"Wei","year":"2015","journal-title":"J. neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib324","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000502562","article-title":"The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells","volume":"105","author":"Weissenrieder","year":"2020","journal-title":"Pharmacology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib325","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib326","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib327","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib328","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib329","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185208","article-title":"Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme","volume":"12","author":"William","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105451_bib331","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1038\/s41598-018-24046-2","article-title":"Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro","volume":"8","author":"Wood","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib332","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39984","article-title":"Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105451_bib333","first-page":"515","article-title":"Over expression of PTEN induces apoptosis and prevents cell proliferation in breast cancer cells","volume":"67","author":"Wu","year":"2020","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib334","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.3390\/ijms22158324","article-title":"The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma","volume":"22","author":"Wu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib335","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib336","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41467-021-22327-5","article-title":"Dominant role of CDKN2B\/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis","volume":"12","author":"Xia","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105451_bib337","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1613332","article-title":"Vaccine therapies for glioma: clinical frontiers and potential breakthrough","volume":"15","author":"Xing","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib338","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biology9090285","article-title":"A glance of p53 functions in brain development, neural stem cells, and brain cancer","volume":"9","author":"Xiong","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.critrevonc.2026.105451_bib339","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105451_bib340","first-page":"363","article-title":"Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition","volume":"21","author":"Xu","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105451_bib341","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1007\/s00330-022-09098-3","article-title":"Editorial comment: \u201cDiffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication\u201d","volume":"32","author":"Yamamoto","year":"2022","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib342","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2022.914618","article-title":"Advances in immune microenvironment and immunotherapy of isocitrate dehydrogenase mutated glioma","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib343","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fcell.2019.00217","article-title":"Novel Function of lncRNA ADAMTS9-AS2 in Promoting Temozolomide Resistance in Glioblastoma via Upregulating the FUS\/MDM2 Ubiquitination Axis","volume":"7","author":"Yan","year":"2019","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib344","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib345","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fonc.2023.1194232","article-title":"Characteristics of glioblastomas and immune microenvironment in a Chinese family with Lynch syndrome and concurrent porokeratosis","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib346","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib347","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092042","article-title":"A High-Grade Glioma, Not Elsewhere Classified in an Older Adult with Discordant Genetic and Epigenetic Analyses","volume":"12","author":"Yuen","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105451_bib348","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI38596","article-title":"P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3","volume":"122","author":"Zerrouqi","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105451_bib349","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/neuonc\/not087","article-title":"IDH1\/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma","volume":"15","author":"Zhang","year":"2013","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib350","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101663","article-title":"GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy","volume":"32","author":"Zhang","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib351","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105451_bib352","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac014","article-title":"Current and future perspectives of chimeric antigen receptors against glioblastoma","volume":"2","author":"Zhang","year":"2022","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.critrevonc.2026.105451_bib353","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.21037\/tcr-20-1718","article-title":"Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib354","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fmolb.2020.562798","article-title":"Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105451_bib355","first-page":"10","article-title":"The p53 Pathway in Glioblastoma","author":"Zhang","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105451_bib356","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41420-024-02085-1","article-title":"The combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis","volume":"10","author":"Zhao","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.critrevonc.2026.105451_bib357","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-017-2738-1","article-title":"Neural stem cells: developmental mechanisms and disease modeling","volume":"371","author":"Zhao","year":"2018","journal-title":"Cell. Tissue Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib358","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105451_bib359","first-page":"2022","article-title":"The global change of gene expression pattern caused by PTEN mutation affects the prognosis of glioblastoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105451_bib360","doi-asserted-by":"crossref","first-page":"21835","DOI":"10.1038\/s41598-023-48777-z","article-title":"Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells","volume":"13","author":"Zhu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105451_bib361","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/erm.12.30","article-title":"The cellular origin for malignant glioma and prospects for clinical advancements","volume":"12","author":"Zong","year":"2012","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105451_bib362","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:25Z","timestamp":1793943745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":362,"alternative-id":["S1040842826003380"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105451","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological strategies for glioblastoma: Current therapies, challenges, and emerging targets","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105451"}}